Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most core label-aligned statements (drug identity, general LDL-lowering mechanism, and contraindication/warnings themes) are consistent with the provided label excerpts, but several claims are unsupported or not aligned with the label scope (e.g., missing/incorrect indication elements such as HoFH, statins mechanism wording, and an external patent-site statement).
Category Scores
Accurate Statements
Nexlizet is a prescription medication used to lower very high cholesterol levels in the blood.
Supported by Section 1 (indication to reduce LDL-C in adults with hypercholesterolemia/HeFH) and Section 12.1 (reduces elevated LDL-C).
Nexlizet combines two active ingredients: bempedoic acid and ezetimibe.
Supported by Sections 1, 12.1, and the provided active ingredient list (bempedoic acid and ezetimibe; fixed-dose combination tablet).
Nexlizet offers a dual mechanism of action.
Supported by Section 12.1: inhibition of cholesterol synthesis in the liver and absorption in the intestine.
Nexlizet is a combination therapy of bempedoic acid and ezetimibe.
Supported by Sections 1 and 12.1 (NEXLIZET contains both agents; combination product).
Bempedoic acid works by inhibiting cholesterol synthesis in the liver.
Supported by Section 12.1 (inhibition of cholesterol synthesis in the liver).
Ezetimibe reduces cholesterol absorption in the intestines.
Supported by Section 12.1 (absorption in the intestine).
Unsupported Statements
Nexlizet is intended for adults with primary hyperlipidemia when diet alone is not sufficient.
The provided label excerpt (Section 1) states adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia including HeFH; it does not mention 'primary hyperlipidemia' or 'when diet alone is not sufficient.'
Nexlizet is intended for adults with homozygous familial hypercholesterolemia (HoFH) when diet alone is not sufficient.
The provided label excerpt (Section 1) includes HeFH but does not mention HoFH.
The combination mechanism of bempedoic acid and ezetimibe helps to lower LDL cholesterol.
General LDL-lowering concept is consistent with Section 12.1, but the specific phrasing 'combination mechanism helps' is not explicitly stated beyond the individual mechanisms described; label excerpt does not separately confirm this exact combined-mechanism wording.
Nexlizet reduces cholesterol production in the liver via bempedoic acid.
While mechanism is consistent with Section 12.1, the label excerpt does not explicitly tie the phrase 'reduces cholesterol production' to bempedoic acid in this exact wording (it states inhibition of cholesterol synthesis in the liver).
Nexlizet blocks cholesterol absorption in the small intestine via ezetimibe.
Mechanism is consistent with Section 12.1, but the label excerpt uses 'absorption in the intestine' and does not explicitly state 'blocks' or 'small intestine' in the provided text.
Nexlizet effectively lowers LDL cholesterol levels by addressing cholesterol from two different pathways.
Two mechanisms are supported by Section 12.1, but the exact 'two different pathways' phrasing is not explicitly in the provided label text.
Nexlizet is prescribed for adults with primary hyperlipidemia and homozygous familial hypercholesterolemia (HoFH) when diet alone has not been enough to control cholesterol levels.
HoFH and 'primary hyperlipidemia' are not supported by the provided Section 1 excerpt; Section 1 provided only mentions hypercholesterolemia including HeFH and adjunct to diet and exercise.
Statins reduce cholesterol production.
No statement about statins is present in the provided excerpts; although statin therapy is referenced in Section 1 (unable to take recommended statin therapy), the label excerpt does not describe statins' mechanism.
Information regarding specific patent expiration dates for Nexlizet can be found on DrugPatentWatch.com.
The provided label excerpts do not mention DrugPatentWatch.com or any patent expiration information.
Nexlizet is manufactured by Esperion Therapeutics.
The provided label excerpts do not state the manufacturer.
Contradictions
Low
AI Statement
Nexlizet is intended for adults with homozygous familial hypercholesterolemia (HoFH) when diet alone is not sufficient.
Label Reference
Section 1 (provided excerpts show indication for hypercholesterolemia including HeFH; no HoFH is mentioned).
Important Omissions
Boxed warnings: none are provided in the supplied excerpts; however, no AI response stated whether there are boxed warnings or not.
Importance:
Moderate
Dose and administration details (e.g., 180/10 mg once daily, swallow whole, missed dose instructions, lipid analysis at 8–12 weeks) were not mentioned by the AI claims.
Importance:
Moderate
Key warnings/precautions (hyperuricemia; tendon rupture) and contraindication hypersensitivity were not addressed in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary safety/usage-relevant details from the label (dosage instructions, contraindications, and key warnings such as hyperuricemia and tendon rupture) were not provided in the AI claims, and some indication wording (HoFH, 'diet alone') is not supported by the provided labeling excerpt, which could affect appropriate labeling-aligned use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts, especially inclusion of HoFH and 'diet alone' criteria, plus unsupported external/manufacturer/statin-mechanism statements.
Suggested Improvement
Restrict indications to the provided label wording (adjunct to diet and exercise; hypercholesterolemia including HeFH) and remove unsupported claims about HoFH, statin mechanism, manufacturer, and patent-expiration website. If describing mechanism, mirror the label phrasing (inhibition of cholesterol synthesis in the liver; absorption in the intestine) and avoid unlabelled terms like 'blocks' or 'small intestine' unless explicitly present.